Clinical Trials for Prinicipal Investigator: Sai-Hong Ignatius Ou

8 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-15-82 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Open
UCI-17-100 A Phase 1/2 Study of alectinib in RET-rearranged non-small cell lung cancer or RET mutated thyroid cancer Open
UCI-17-61 [EXEMPT - RETROSPECTIVE CHART REVIEW] Retrospective survival analysis among patients with non-small cell lung cancer harboring MET exon 14 mutations Open
UCI-17-81 [EXEMPTED-EXPANDED ACCESS] An expanded access protocol for lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations Open
UCI-18-14 A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors Open
UCI-18-22 A Phase I/II study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Open
UCI-18-49 (Emergency Use) Single-Patient Access Treatment Using Osimertinib And Blu-667 For Advanced Non-Small Cell Lung Cancer With A Concomitant EGFR Mutation And Ret Fusion. Patient K.M. Open